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ABSTRACT
CURCUMIN AND ITS OXIDATIVE DEGRADATION PRODUCTS: THEIR
COMPARATIVE EFFECTS ON INFLAMMATION
MAY 2016

JULIA ZHU, B.S., CORNELL UNIVERSITY
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Dr. Guodong Zhang

The anti-inflammatory agent curcumin degrades rapidly, leading to speculations that
curcumin’s reported effects stem from its degradation products. Curcumin can degrade
via hydrolysis, and more recently it was discovered that curcumin can degrade via
oxidation at physiological pH. Additionally, bicyclopentadione is the major degradation
product from this oxidation reaction. Evidence from the literature suggests that curcumin
degrades primarily through oxidation. However, the biology of the oxidation products is
not well characterized, and there is debate on whether oxidation intermediates or
curcumin itself is more biologically active. To further elucidate the biology of the
oxidation products, their effects on inflammation were examined. RAW264.7 murine
macrophage cells were stimulated with E. coli lipopolysaccharide (LPS) and treated with
curcumin, curcumin’s total oxidative degradation products, and bicyclopentadione.
Curcumin strongly decreased LPS-induced nitric oxide production and iNOS expression
in a dose dependent manner; total degradation products slightly decreased nitric oxide
iv

production and iNOS expression, while bicyclopentadione failed to decrease either.
Additionally, curcumin was significantly more effective than either bicyclopentadione or
total degradation products in inhibiting COX-2 expression. iNOS and COX-2 arise from
the activation of the NF-kB pathway, which curcumin is known to modulate; thus, the
oxidation products’ effect on key proteins in this pathway was also examined. Neither
total degradation products nor bicyclopentadione inhibited translocation of NF-kB into
the nucleus, prevented degradation of IκBα, nor inhibited phosphorylation of IKK as
effectively as curcumin. In conclusion, curcumin is significantly more effective at
inhibiting inflammation than the oxidation degradation products.
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CHAPTER 1
LITERATURE REVIEW
1.1 Introduction
Substantial studies have shown that curcumin, a bis-α,β-unsaturated β-diketone
compound found in turmeric, has potent anti-cancer and anti-metastatic actions 1. Indeed,
many animal studies have shown that curcumin suppressed primary tumor growth of
many types of cancers, including but not limited to pancreatic cancer 2, breast cancer 3,
cervical cancer 4, lung cancer 5, and colon cancer 6. Tumor metastasis, the process by
which tumor cells spread from the primary tumor site to other organs, causes approximate
90% of human cancer deaths 7. Animal experiments have also shown that curcumin
inhibited tumor metastasis of prostate cancer 8-10, breast cancer 11-14, colorectal cancer 15,
and pancreatic cancer 16. Human studies also support the cancer risk reducing effects of
curcumin. In a Phase II clinical trial of colorectal cancer, daily intake of 4 grams of
curcumin for a month caused a ~40% reduction of aberrant crypt foci 17. In another Phase
II human clinical trial, daily intake of 8 grams of curcumin demonstrated anti-cancer
efficacy in some patients with advanced pancreatic cancer 18. Together, these results
make curcumin a promising dietary compound for cancer prevention and/or treatment.
Curcumin inhibits tumor progression and metastasis through multiple possible
mechanisms. Previous studies demonstrated that curcumin inhibited cancer cell
proliferation by inducing cell cycle arrest and apoptosis and inhibiting cancer cell
migration and invasion, which are critical cellular processes involved in tumor
progression and metastasis 19. Curcumin has also been shown to inhibit inflammation by
suppressing NF-kB signaling and modulating the expressions of inflammatory cytokines
1

and microRNAs in cancer cells, leading to reduced cancer progression and metastasis
9,10,15,20

. Besides directly targeting cancer cells, curcumin can also target tumor-associated

endothelial cells, resulting in reduced tumor angiogenesis and associated tumor
progression and metastasis 21. In addition, a recent study showed that curcumin potently
inhibited lymphangiogenesis (de novo lymphatic formation), which is a critical process in
mediating tumor metastasis 22. In summary, curcumin can inhibit tumor growth and
metastasis through targeting several critical cellular processed involved in tumorigenesis,
including cancer cell proliferation and motility, tumor inflammation, angiogenesis and
lymphangiogenesis.
Although the cancer risk-reducing effects of curcumin have been well characterized,
the molecular mechanisms by which curcumin inhibits cancer are not well understood.
Curcumin has poor metabolic and chemical stability, making it difficult to determine
whether the observed anti-cancer effects are mediated by curcumin itself or its
metabolites. Indeed, many studies have shown that curcumin has a poor
pharmacokinetics profile: one study showed that after a single oral dose of 10 or 12
grams of curcumin, free form of curcumin was barely detected in human plasma 23. The
low levels of curcumin in circulation make it difficult to understand how curcumin exerts
systematic anti-cancer effects, particularly in its inhibitory effect on non-gastrointestinal
tract cancer types. This leads to hypothesis that the biological effects of curcumin are
mediated by its metabolites. However, many studies have shown that most of the
enzymatic metabolites of curcumin are either biologically less active or inactive
compared to curcumin. For example, curcumin sulfate and curcumin glucuronide, which
are the major metabolites of curcumin after oral consumption, have been shown to have
2

dramatically reduced biological activities 22,24-26. These results suggest that the biological
activities of curcumin are unlikely to be mediated by these enzymatic metabolites.
Besides its poor metabolic stability, curcumin also has poor chemical stability: it
rapidly degraded in aqueous solution at physiological pH with a half-life of several
minutes, leading to rapid formation of various degradation products 27,28. These chemical
degradation products include two classes of compounds: (1) alkaline hydrolysis products,
where the hydroxyl ion (OH-) attacks the carbonyl group of curcumin, generating
hydrolyzed products such as ferulic acid, vanillin, ferulaldehyde, and feruloyl methane 29;
(2) autoxidation products, where curcumin is first converted to a phenolic radical, which
then migrates to the conjugated heptadienedione chain and initiates a chain reaction of
curcumin degradation to generate cyclized compounds such as bicyclopentadione 27,28,30.
Recently, several studies have suggested that the biological activities of curcumin could
be mediated by its degradation products. In this chapter, the chemistry and biology of the
curcumin degradation products will be discussed.
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1.2 Chemistry of alkaline hydrolysis of curcumin
Wang et al. discovered that curcumin rapidly degraded in aqueous solution (e.g.
phosphate, citrate-phosphate, carbonate buffers and serum-free cell culture medium) in a
pH-dependent manner: in acidic environments (pH = 3-6.5), the half-life of curcumin in
aqueous buffer was around 100-200 min, while at neutral and alkaline environments (pH
>7), the half-life of curcumin was around 10 min. HPLC analysis showed that the
degradation products included vanillin, ferulic acid, ferulic aldehyde, feruloyl methane,
and trans-6-(4'-hydroxy-3'-methoxyphenyl)-2,4-dioxo-5-hexenal 29,31, which are breakdown products of curcumin. Together, these results suggest that these degradation
products are formed through a hydroxyl ion (OH-)-dependent mechanism (see Fig. 1) 32.
Of these degradation products, ferulic acid and feruloyl methane are produced from the
alkaline hydrolysis of the diketone group 32, and feruloyl methane can be hydrolyzed
further to generate vanillin 31.

Figure 1: The hydrolytic degradation pathway of curcumin. In the presence of (OH-), curcumin can be
hydrolyzed into several different products, including ferulic acid, feruloyl methane, and vanillin.

Recent research suggests that the alkaline hydrolysis pathway has a limited
contribution to curcumin degradation in aqueous buffers. First, the hydrolysis-derived
products are minor compounds in curcumin degradation products. Wang et al found that
vanillin, ferulic acid, and feruloyl methane were minor degradation products compared to
trans-6-(4'-hydroxy-3'-methoxyphenyl)-2,4-dioxo-5-hexenal at 280nm 29. Second, the

4

comparative stabilities of curcumin and its analogues (such as dimethoxycurcumin,
demethoxycurcumin, and didemethoxycurcumin) further support that the hydrolysis
mechanism is not a major pathway in mediating curcumin degradation. Since the
curcumin analogues have the same conjugated heptadienedione chain as curcumin; it
follows that if alkaline hydrolysis mechanism is the primary mediator of curcumin
degradation, these compounds should have similar stability. However, the analogues are
much more stable than curcumin 33,34: For example, after 1 hour incubation in phosphate
buffer, HPLC analysis showed that curcumin rapidly degraded, while
dimethoxycurcumin was very stable 33, suggesting that the alkaline hydrolysis
mechanism has a limited contribution in mediating curcumin degradation.
1.3 Biology of hydrolysis products
Of the aforementioned hydrolysis products, the biological effects of vanillin and
ferulic acid have been well studied. Both compounds have been shown to have anticancer effects in vitro and in vivo. Some of the other hydrolysis degradation products
have also been studied, though not to the extent of vanillin and ferulic acid. For example,
ferulaldehyde has been shown to inhibit inflammatory responses in mice 35. In the section
below, we will discuss the anti-cancer effects and mechanisms of vanillin and ferulic acid.
1.3.1 Ferulic acid
Ferulic acid has been shown to inhibit cancer and inflammation in cell culture models.
After 24 h treatment, 500-1000 µM ferulic acid suppressed 20-25% of cell proliferation
in lung, colon and oral cancer cells 36,37; after 48 hour treatment, curcumin at a lower dose
(~30 µM) inhibited approximately 50% and 25% of cellular proliferation in HepG2
hepatoma cells 38 and PC-3 prostate cancer cells, respectively 39. Ferulic acid has also
5

been shown to inhibit cell cycle progression and induce apoptosis in cancer cells. At a
dose of 300-1000 µM, ferulic acid can decrease expression of genes involved in G1 cell
cycle arrest in PC-3 cells 39 and cause G2 arrest in malignant oral cancer cells 37. It has
also been shown to inhibit cellular migration and invasion in cancer and endothelial cells,
which are critical processes involved in tumor metastasis. A wound healing assay in
A549 lung cancer cells showed that ferulic acid at 200 µM inhibited ~65% of cell
migration 36. At a dose range of 2.5-10 µM, ferulic acid inhibited fibroblast growth
factor-1 (FGF1)-induced migration and invasion, as well as expressions of matrix
metalloproteinase-2 (MMP-2) and MMP-9, in human umbilical vein endothelial cells
(HUVEC) 40. Ferulic acid has also been shown to suppress inflammation: In RAW 264.7
macrophage cells, ferulic acid inhibited IKK-α/β phosphorylation and subsequent nuclear
translocation of NF-kB, suggesting that ferulic acid inhibited inflammation by
suppressing NF-kB pathway 41.
Animal experiments have also shown the anti-cancer effects of ferulic acid. In an
azoxymethane (AOM)-induced colon cancer model in F334 rats, continuous oral
administration of 500 mg/kg ferulic acid reduced aberrant crypt foci formation per colon
by 30.5% 42. In a 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer model
in Sprague-Dawley rats, oral administration of 40 mg/kg ferulic acid for 1 week before
DMBA induction and throughout the 16 week experimental period reduced mammary
cancer incidence by 80% 43. In a DMBA-induced skin tumor model in Swiss albino mice,
oral administration of 40 mg/kg ferulic acid abolished tumor progression 44.
Intraperitoneal injection of 50 mg/kg ferulic acid 1 hour prior to exposure to UV light
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decreased tumor number and volume by 66% and 80% respectively in Swiss albino mice
45

.
However, the biological activities of ferulic acid are less potent compared to

curcumin. For example, curcumin has been shown to be >160-fold more potent in
inhibiting cellular proliferation of human peripheral blood mononuclear cells 46. In
addition, ferulic acid at a dose range of 100-1000 µM did not have any effect on cellular
proliferation of MDA-MB-231 breast cancer cells, while curcumin at a dose as low as 30
µM inhibited ~50% of MDA-MB-231 proliferation 47. In a 12-O-tetradecanoylphorbol13-acetate (TPA)-induced skin cancer model in CD-1 mice, topical application of 10 µM
suppressed the number of skin tumors by 98%, whereas at the same dose ferulic acid only
caused a 35% inhibition 48. In a mouse edema inflammation model, topical application of
1 µM curcumin almost abolished TPA-induced inflammation, while ferulic acid at the
same dose only caused a 16% inhibition 49. Many other studies have also shown that
ferulic acid was dramatically less active compared with curcumin 49-52.
1.3.2 Vanillin
Similar to ferulic acid, vanillin has also been shown to have anti-cancer and antiinflammatory effects. However, the doses of vanillin used in these studies were far higher
than the amount that would be found as a curcumin degradation product. For example,
HepG2 in remained viable at concentrations as high as 10 mM 53. In other words, as a
degradation product, vanillin would not be in a biologically relevant concentration that
could induce anti-cancer or anti-inflammatory effects. Despite this setback, vanillin
nevertheless has been found to have some biological effects, provided that high doses
were used.
7

Vanillin has been shown to modulate cell cycle, and apoptosis in several different cell
lines, albeit at high doses. For example, the compound has been shown to modulate cell
cycle by inducing G1 and G2 arrest in HT-29 cells 54, downregulating genes associated
with cell cycle such as cyclin A2 in HepG2 cells 53, and by increasing expression of p21,
a protein that inhibits cyclin B and leads to G2 arrest 55. Vanillin also induced apoptosis
in HT-29 cells 54 and further sensitized HeLa cervical cancer cells to tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL), a cytokine that that is capable of
inducing apoptosis in cancer cell lines 56. In the same cell line, vanillin enhanced
cleavage of caspase-3 and PARP, both of which are apoptotic proteins that are activated
by cleavage 56.
Vanillin is also capable of attenuating cancer metastasis by modulating angiogenesis,
cell invasion and migration in vitro. In A549 lung cancer, 4T1 mammary adenocarcinoma,
and HepG2 hepatocarcinoma cells, vanillin was found to decrease cell invasion and
migration at a dose range of 0.5-1 mM without affecting cell viability 57-59; vanillin also
suppressed angiogenic activity in A549 cells 57. Vanillin inhibited metastasis through
suppressing MMP-9 and phosphoinositide 3-kinase (PI3K)/Akt pathway, which play
critical roles in cell migration 59.
In addition to its anti-cancer effects, vanillin has also been shown to have antiinflammatory effects. In a dose range of 100-500 µM, vanillin inhibited COX-2 mRNA
expression in RAW 264.7 mouse macrophage cells stimulated with lipopolysaccharide
(LPS) 60. Like ferulic acid, vanillin suppressed inflammation through the NF-κB pathway.
In a dose range of 0.25-5 mM, vanillin was shown to inhibit phosphorylation of IκBα in
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HepG2 cells 59, phosphorylation of p65 in HeLa cells 56, and NF-κB binding to the
consensus sequence in RAW 264.7 cells 60.
Despite vanillin’s potential as an anti-cancer and anti-inflammatory agent, even when
compared to ferulic acid, the concentration of vanillin required in the studies were often
in the millimolar range, while the dosage used for ferulic acid was generally lower; since
ferulic acid has been shown to be biologically less effective than curcumin, it is unlikely
that vanillin contributes to the biological effects of curcumin. Indeed, the IC50 for vanillin
for suppressing peripheral-blood mononuclear cell (PBMC) proliferation was 260 times
higher than that curcumin 46. Curcumin at a dose of 30µM inhibited proliferation of
human breast cancer MDA-MB-231 cells by 50%, while vanillin was unable to inhibit
proliferation of the same cell line, even at a dose as high as 1 mM 47.
1.4 Chemistry of autoxidation products of curucmin
Griesser et al. found that besides alkaline hydrolysis, curcumin can also be degraded
via an autoxidation process 28. The autoxidation process was pH-dependent with the
highest rate at pH = 8, which was consistent with a previous study 29. During this process,
equimolar amount of oxygen was consumed to degrade curcumin, suggesting that an
oxidation reaction is involved in curcumin degradation 28. Co-addition of COX-2 enzyme
accelerated curcumin degradation, and co-addition of hydrogen peroxide further
increased COX-2-mediated curcumin degradation 28.
Structural analysis of the autoxidation products have shown that the most abundant
degradation product was bicyclopentadione, which has incorporated two oxygen atoms
into the structure of curcumin, consistent with the stoichiometric consumption of oxygen
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in curcumin degradation 28. Further structural analysis of other degradation products
suggests that curcumin degradation in aqueous buffer could happen through a mechanism
comparable to that of lipid peroxidation. The first step of curcumin degradation is the
hydrogen dissociation from the phenolic group to form a phenolic radical, which then
migrates to the conjugated heptadienedione chain and leads to the formation of cyclized
compounds such as bicyclopentadione derivatives of curcumin 27,28,30. The radical can
then be transferred to another curcumin molecule, resulting in a chain reaction that causes
curcumin to rapidly degrade 30.
Recent research further suggests that this autoxidation mechanism is the major
pathway in mediating curcumin degradation 33. It was recently shown that a wide range
of redox-active antioxidants with diverse structures, including gallic acid, ascorbate
(vitamin C), tert-butylhydroquinone (TBHQ), caffeic acid, rosmarinic acid, and Trolox (a
water-soluble analogue of vitamin E), dramatically enhanced curcumin stability in
aqueous buffer, supporting the hypothesis that the autoxidation pathway is the major
process mediating curcumin degradation. Antioxidant could also enhance curcumin
stability in vivo: when mice were treated with both curcumin and TBHQ for one hour, the
amount of curcumin present in plasma was approximately 4-times higher compared to
that treated with curcumin alone 33. As an antioxidant itself, curcumin can scavenge free
radicals by donating an electron to the free radical, thus becoming a stable radical itself
61-63

. Antioxidants themselves can be stabilized by other antioxidants if the electron-

donating potential of one of the them is higher than the other 64. The electrochemical
potential of curcumin has been reported as 0.66V 65; comparatively, the electrochemical
potential of antioxidants such as ascorbate, Trolox, and caffeic acid have been reported as
10

0.282V 64, 0.48V 64, and 0.45V 66 respectively. In other words, the aforementioned
antioxidants are able to stabilize curcumin due to their higher electron-donating potential.
Structure and activity relationship study showed that several structural moieties of
curcumin are critical for curcumin stability. These structural moieties include: (1) the
phenolic group: previous studies have shown that dimethoxycurcumin, in which the
radical-initiating phenolic (-OH) groups are converted to methoxy groups (-OCH3), was
highly stable in aqueous buffer, cultured cells and animals 30,33, suggesting the critical
role of the phenolic group in curcumin stability. Indeed, only ~20% of
dimethoxycurcumin dissolved in phosphate buffer degraded after 60 minutes, whereas
curcumin had already degraded by 80% within the first 10 minutes 33. In addition, several
studies have shown that dimethoxycurcumin exerts more potent anti-proliferative and
anti-inflammatory effects compared to curcumin 67-69. The enhanced stability of
dimethoxycurcumin can be explained by the autoxidation mechanism: since the hydrogen
dissociation from the phenolic group to form a phenolic radical is the first step to initiate
curcumin degradation, blocking this group would dramatically enhance curcumin
stability; (2) ortho-substitution of phenolic group: recent research has shown that the
ortho-substitution groups also play important roles in curcumin stability, though more
studies are needed to clarify the structure and activity relationship. For example,
demethoxycurcumin, in which the ortho-substitution group is changed from methoxy to
hydrogen, showed dramatically enhanced stability compared to curcumin 30,34. This can
also be explained by the autoxidation mechanism: as discussed earlier, the first step of
curcumin degradation is the formation of the phenolic radical (Ph-O●), and the rate of p
radical formation is dependent on the bond dissociation energy of the phenol group (Ph11

OH), which is affected by the electron-donating properties of the substitution groups on
the aromatic ring 70. Compared to hydrogen, methoxy group has stronger electrondonating properties; therefore, curcumin, which possess an ortho-substitution of methoxy
group, will generate the phenolic radical more easily than demethoxycurcumin. The same
mechanism can also explain the enhanced stability of bisdemethoxycurcumin compared
to curcumin 34; (3) the conjugated heptadienedione chain: previous studies have shown
that tetrahydrocurcumin, in which the carbon-carbon double bonds in the conjugated
heptadienedione chain were reduced to single bonds, has enhanced stability compared to
curcumin 71. This enhanced stability could also be explained by the autoxidation
mechanism, as structural changes of the heptadienedione chain block the radical
migration and subsequent formation of bicyclopentadione derivatives of curcumin.
Together, these structure and activity relationship studies could help us to better
understand the mechanism of curcumin stability, leading to design of better curcuminbased therapeutics.
1.5 Biology of autoxidation products of curcumin
To date, the biological activities of the curcumin oxidation products are largely
unknown. Ketron et al have suggested that the reactive intermediates generated during
curcumin degradation could increase topoisomerase II-mediated DNA cleavage 72.
Topoisomerase II is an enzyme responsible for preventing under- or over-winding of
DNA during replication by covalently binding to the double stranded DNA, cleaving both
strands, unwinding them, and finally ligating them. Ketron et al found that treatment with
curcumin alone or potassium ferricyanide alone could not enhance topoisomerase II
mediated-DNA cleavage; however, their combination enhanced DNA cleavage in a dose12

dependent manner. The stable degradation product of curcumin bicyclopentadione itself
had little effect on DNA cleavage with or without the presence of potassium ferricyanide
72

. Together, these results indicate that the reactive intermediates formed during curcumin

degradation, such as the quinone methide radical intermediates, could contribute to the
topoisomerase II-induced DNA cleavage 72.
If curcumin oxidation products, but not the parent compound, were the cause of
curcumin’s biological efficacy, it follows that if curcumin degradation was suppressed,
the biological activities of curcumin would be attenuated. However, a recent study did
not support this hypothesis. Instead, the results showed that when curcumin degradation
was suppressed through co-addition of serum or antioxidants, the biological activities of
curcumin were dramatically enhanced 29. These results suggest that curcumin, but not its
degradation products, have potent biological activities. Further studies are needed to
better characterize the role of autoxidation in the biological activities of curcumin.
1.6 Conclusion
Although curcumin has been shown to have anti-cancer and anti-inflammatory effects,
the compound has been hampered by the lack of metabolic and chemical stability. In
alkaline aqueous solutions, curcumin can undergo hydrolysis and oxidation. Through the
hydrolysis pathway, curcumin degrades into hydrolysis products such as vanillin, ferulic
acid, ferualdehyde, and feruloylmethane. Through autoxidation, curcumin forms a
phenolic radical that incorporates oxygen into the reaction; one of the final products is
bicyclopentadione 28. Based on evidence from the current literature, curcumin most likely
degrades through oxidation rather than through hydrolysis.
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The evidence for the oxidative pathway lies in the evidence from structurally similar
curcumin analogues and the stabilizing effects of antioxidants on curcumin. If curcumin
degraded primarily through hydrolysis, the functional phenolic group would have little
effect on the stability of curcumin, since hydrolysis occurs on the diketone group on the
heptadioenone bridge; however, data from curcumin analogue studies show that the
phenolic functional groups greatly affect stability. Furthermore, curcumin can be
stabilized by other antioxidants in basal media. If hydrolysis was the primary degradation
pathway, antioxidants would have little effect on curcumin’s stability since during
hydrolysis curcumin does not form radicals.
Because curcumin autoxidation is a recent discovery, the biology of autoxidation
products of remains poorly characterized. It has been suggested that curcumin exerted its
effects through its oxidative intermediates such as its quinone methides 72. However,
when curcumin is stabilized through co-addition of serum or antioxidants, the biological
activities of curcumin were greatly enhanced, suggesting that curcumin, but not its
degradation products, has potent biological activities 33 .
In conclusion, emerging research supports the hypothesis that the autoxidation
pathway is the major mechanism mediating curcumin degradation, but further studies are
needed to characterize the roles of autoxidation in the biological effects of curcumin. In
next chapter, the biological activities and mechanisms of the oxidative degradation
products of curcumin will be examined.
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CHAPTER 2
CURCUMIN, BUT NOT ITS OXIDATIVE DEGRADATION PRODUCTS,
ATTENUATES INFLAMMATORY RESPONSES AND NF-kB SIGNALING
2.1 Introduction
Curcumin can autoxidize to bicyclopentadione at physiological pH 30. To date, there
is little literature on the biological activity of curcumin oxidation products. Ketron et al
found that curcumin alone did not increase topoisomerase II-mediated DNA cleavage, but
when a potassium ferricyanide, a Fe3+ source, was added to curcumin, DNA cleavage
occurred. The associated DNA cleavage corresponded with a decrease in curcumin's peak
at 430nm and an increase in the oxidation products peak at 263nm. Since
bicyclopentadione, one of the major oxidation products, had little effect on DNA
cleavage regardless of whether Fe3+ was present, Ketron et al concluded that the DNA
cleavage was caused by curcumin oxidation intermediates 72. However Nimiya et al
reported that curcumin is stabilized by the presence of another antioxidant, leading to
enhanced anti-proliferative activities on MC38 colon cancer cells in free media 33.
Antioxidants such as ascorbic acid would stabilize the curcumin radical, which would
otherwise undergo autoxidation. In other words, the study suggests that the biology of
curcumin does not come from the oxidative degradation products.
Due to the conflicting data on the biology of curcumin oxidative degradation products,
further studies must be conducted to elucidate their effects. To date, there have been no
studies on the effects of curcumin’s oxidative degradation products on inflammation.
Thus, the objective of this study was to compare the effects of these products to curcumin
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in terms of inflammation, and to provide further insight on biology of the degradation
products.
2.2 Materials and Methods
2.2.1 Curcumin degradation products and cell culture
Curcumin was chemically synthesized in the laboratory. Total degradation products
of curcumin (TDP) were obtained by incubating curcumin in pH 7.4 phosphate buffer and
extracting them with ethyl acetate. Bicyclopentadione (BCPD) was isolated from the total
degradation products. RAW 264.7 murine macrophage cells were maintained in
Dulbecco’s modified Eagle medium (DMEM, Lonza, Allendale, NJ) supplemented with
10% fetal bovine serum (Corning Inc, Corning, New York) and antibiotics (100 U/mL
penicillin and 100 μg/mL streptomycin, Lonza, Allendale, NJ) in a 37ºC incubator with 5%
CO2.
2.2.2 Nitric oxide measurement and cell viability
RAW 264.7 cells were seeded into 96-well plates in complete medium (DMEM that
containing 10% fetal bovine serum) After 24 hour incubation, cells were treated with test
compounds and 0.5 μg/mL LPS. After another 24 hours, cell medium was transferred into
another 96-well plate and an equal volume of Griess reagent (0.1% NED, 1%
sulfanilamide, 4% phosphoric acid) was added to the cell medium. The absorbance was
read at 540 nm. Cell proliferation was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay.
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2.2.3 Sample preparation for iNOS and COX-2 Western blots
RAW 264.7 cells were seeded in 6-well plates for 24 hours in complete medium.
After 24 hour incubation, cells were treated with the test compounds and 0.5 μg/mL LPS.
After another 24 hours, the medium was decanted and the cells were washed with icecold PBS and lysed with RIPA buffer containing phosphatase inhibitors and 1 mM
EDTA. The total protein in the lysates was quantified using a BCA kit (ThermoScientific, Waltham, MA). Laemli loading buffer (Amresco, Solon, OH) was added into
all samples, which were stored at-20ºC until ready for use.
2.2.4 Sample preparation for IκBα and p-IKK Western blots
RAW 264.7 cells were seeded in 6 well plates for 24 hours in complete medium.
Cells were pre-treated with either the test compounds or DMSO vehicle for 1.5 hours.
The cells were then treated with 0.5 μg/mL LPS for 20 minutes. Samples were collected
according to the procedure described above.
2.2.5 Sample preparation for NF-κB translocation
RAW 264.7 cells were seeded into 60mm plates for 24 hours in complete medium.
Cells were pre-treated with either the test compound or DMSO vehicle for 1.5 hours. The
cells were then treated with 2 μg/mL LPS for 30 minutes. The nuclear extracts were
collected using nuclear extraction kit (Cayman Chemicals, Ann Arbor, MI) according to
the manufacturer’s instructions (a modification was to wash the nuclear pellet with icecold phosphate saline buffer 3 times and centrifuging the suspension at 4500 g between
each wash).
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2.2.6 Western Blotting
Equal amounts of protein were resolved with 8% SDS-PAGE gel and transferred onto
nitrocellulose membrane. The membrane was washed with TBS, blocked with 5% bovine
serum albumin, incubated with the primary antibodies, and rocked gently at 4ºC
overnight. After primary incubation, membranes were washed with TBS containing
0.05% TWEEN before probing with LI-COR IRDye 800CW Goat anti-Rabbit and IRDye
680RD Goat anti-Mouse secondary antibodies at room temperature. Membranes were
washed again and scanned with the Odyssey imaging system (LICOR, Lincoln, NE).
Western blot signal quantification was performed in ImageJ. Cytoplasmic protein signals
were normalized with the β-actin signal, while the nuclear protein signals were
normalized with the lamin signals. The following primary antibodies were used: antiiNOS, anti-COX-2, anti-IκBα, anti-p-IKK, anti-NF-κB p65 (Cell Signaling, Danvers,
MA), anti- β-actin (Sigma, St. Louis, MO), and anti-lamin A/C (Santa Cruz, Dallas, TX).
Anti-Hsp90 (Santa Cruz, Dallas, TX) was used to check for contamination in the nuclear
fraction.
2.2.7 Statistical Analysis
All results are expressed as mean  standard deviation (S.D.). All statistical
calculations were performed using ANOVA followed by Tukey’s test with the assistance
of the R statistical software. If a significant difference among the interaction between
treatment and dose was found, the interaction was separated by either treatment or dose
and analyzed again with ANOVA followed by Tukey’s. Statistical significance was
considered significant at p<0.05. Results are from 3 independent experiments.
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2.3 Results
2.3.1 Curcumin, not its degradation products, attenuates LPS-induced nitric oxide
production
Under inflammatory conditions, nitric oxide is synthesized, and curcumin is a known
nitric oxide inhibitor 73. In this experiment, the comparative effects of curcumin, TDP,
and BCPD on LPS-induced nitric oxide production in RAW 264.7 were examined. The
cells were treated with these test compounds at several different doses in combination
with LPS for 24 hours. Since there was a significant difference among the interaction of
treatment and dose, the interaction was separated by dose to determine the effect of the
treatment. Curcumin significantly decreased LPS-induced nitric oxide production, which
is consistent with previous reports 73. TDP also showed a slight dose-dependent decrease
in nitric oxide production. On the other hand, treatment with BCPD did not decrease
nitric oxide production (Fig. 2).
2.3.2 Curcumin, but not its degradation products, inhibits LPS-induced iNOS
expression
Because nitric oxide is produced from iNOS under inflammatory conditions 74, the
comparative effects of curcumin, TDP and BCPD on iNOS expression were examined
(Figure 3). Since there was a significant difference among the interaction of treatment
and dose, the interaction was partitioned by treatment to determine the effect of the
treatment dose on iNOS expression. Starting from 3.68 μg/mL, curcumin significantly
inhibits iNOS expression in RAW 264.7 cells stimulated with LPS, consistent with
previous reports 75. TDP appeared to have a small dose-dependent effect on iNOS
inhibition, while BCPD failed to significantly inhibit iNOS expression regardless of dose.
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Figure 2: The effects of curcumin, TDP, and BCPD on LPS-induced nitric oxide production.
Concentration of nitric oxide in medium was calculated as the fraction of the absorbance of the
treatment over the absorbance of the LPS control. Results are represented as meansS.D from three
independent experiments. A significant difference among interaction of treatment and dose
concentration was found, so the interaction was separated by dose to examine the effect of the
treatment at given certain dose. * indicates significance from the LPS only control at p<0.05. Different
letters indicate significant difference between the treatments at the given concentration (p<0.05).

2.3.3 Curcumin, but not its degradation products, inhibits LPS-induced COX-2
expression
Like iNOS, COX-2 is another protein that is produced under inflammatory conditions.
To examine the comparative effects of curcumin and the oxidative degradation products
on COX-2 expression, RAW-264.7 cells were treated with 0.5 μg/mL LPS and 9.2 μg/mL
of curcumin, TDP, or BCPD for 24 hours. COX-2 expression was then examined with
Western blotting (Figure 4). Curcumin greatly inhibited COX-2 expression, consistent
with previous reports 75; however, neither the TDP nor BCPD significantly inhibited
COX-2 expression.
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Figure 3: The effects of curcumin, TDP, and BCPD on iNOS expression.
RAW 264.7 cells were treated with test compound and 0.5 μg/mL LPS for 24 hours, iNOS expression
was analyzed by Western blotting (A). iNOS signals were normalized with the β-actin signals and the
intensity was calculated as the fraction of the averaged normalized LPS signal. Results are represented
as meansS.D from three independent experiments (B). Since there was a significant difference in the
interaction of treatment and dose, the interaction was separated by dose to examine the effect of
treatment at a given dose. * indicates significance from the LPS-only control at p<0.05. Different
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2.3.4 Curcumin, but not its degradation products, inhibits LPS-induced p65
translocation
Both iNOS and COX-2 are produced when the NF-κB pathway is activated 76. Under
inflammatory conditions, the NF-κB dimer translocates into the nucleus and initiates the
transcription of many inflammatory mediators such as iNOS and COX-2 77. Curcumin is
known to inhibit translocation of NF-κB 78,79. To assess the ability of curcumin’s
degradation products to inhibit NF-κB translocation, RAW 264.7 cells were pre-treated
with 36.2 μg/mL of test compound for 1.5 hours, followed by a 30 minute induction of
inflammation with 2 μg/mL LPS. The nuclear fraction was collected and subjected to
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Western blotting. Curcumin inhibited the translocation of p65 into the nucleus, which is
consistent with previous reports 79; neither total degradation products nor
bicyclopentadione significantly inhibited the protein’s translocation.
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Figure 4: The effects of curcumin, TDP, and BCPD on COX-2 expression
RAW 264.7 cells were incubated with 0.5 μg/mL LPS and 9.2 μg/mL of each test compound for 24
hours, COX-2 expression was analyzed by Western blotting (A). COX-2 signals were normalized with
the β-actin signals and the intensity was calculated as the fraction of the averaged LPS signal. Results
are represented as meansS.D from three independent experiments (B). Different letters indicate
significant difference between the groups at p<0.05

2.3.5 Curcumin, but not its degradation products, inhibits LPS-induced IκBα
degradation and IKK phosphorylation
Upstream of NF-κB nuclear translocation are the proteins IκBα and IκB kinase (IKK).
IκBα is responsible for sequestering NF-κB in the cytoplasm; under inflammatory
conditions, IκBα is phosphorylated by IKK and is sent for degradation. IKK itself is
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RAW 264.7 cells were pre-treated with 36.2 μg/mL test compound or DMSO vehicle for 1.5 hours,
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Western blotting (A). p65 signals were normalized with the lamin signals and the intensity was
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independent experiments (B). Different letters indicate significant difference between the groups at
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also activated by phosphorylation. Curcumin is known to modulate the NF-κB pathway
by inhibiting degradation of IκBα and phosphorylation of IKK 79. To assess the effects of
curcumin’s oxidative degradation products on these two proteins, RAW 264.7 cells were
pre-treated with 36.2 μg/mL of curcumin, TDP, or BCPD for 1.5 hours, followed by 20
minute stimulation of 0.5 μg/mL LPS; the cell lysate was collected and subjected to
Western blotting (Figures 6-7). Curcumin rescued IκBα from degradation during LPS-
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induced inflammation, whereas neither TDP nor BCPD significantly inhibited its
degradation. Additionally, curcumin inhibited phosphorylation of IKK, whereas neither
TDP nor BCPD significantly inhibited IKK phosphorylation
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Figure 6: The effects of curcumin, TDP, and BCPD on IκBα degradation.
RAW 264.7 cells were pre-treated with incubated 36.8 μg/mL test compound for 1.5 hours followed
by 0.5 µg/mL LPS stimulation for 30 minutes. IκBα signals were normalized with the β-actin signals.
Relative intensity was calculated as the fraction of the DMSO (No LPS) control. Results are
represented as meansS.D from three independent experiments (B). Different letters indicate
significant difference between the groups at p<0.05

2.4 Discussion
The results of this study further support that curcumin, but not its oxidative
degradation products, is biologically active. Curcumin is known for its anti-inflammatory
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Figure 7: The effects of curcumin, TDP, and BCPD on IKK phosphorylation.
RAW 264.7 cells were pre-treated with incubated 36.8 μg/mL of each treatment for 1.5 hours
followed by 0.5 μg/mL LPS stimulation for 30 minutes (A). IKK signals were normalized with the
actin signal. IKK phosphorylation intensity was calculated as the fraction of the LPS control. Results
are represented as meansS.D from three independent experiments (B). Different letters indicate
significant difference between the groups at p<0.05.

effects via the NF-κB pathway, and the results for curcumin are consistent with previous
studies 73,78,79. On the other hand, neither TDP nor BCPD was as effective in inhibiting
nitric oxide production, iNOS and COX-2 expression, translocation of p65 into the
nucleus, and NF-κB pathway proteins upstream of p65 translocation. Total degradation
products showed a slight dose-dependent decrease in both nitric oxide production and
iNOS expression, but did not inhibit expression of COX-2, degradation of IκBα,
phosphorylation of IKK, and translocation of p65. The slight dose-dependent decrease
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may be attributed to the residual curcumin that may have been present in the degradation
mixture. BCPD showed no significant effect in all the experiments performed. Although
high doses of each test compound were used for the NF-κB experiments, the results
nevertheless suggest curcumin is more biologically active than the oxidation products.
In conclusion, curcumin’s oxidative degradation products, particularly
bicyclopentadione, have little anti-inflammatory effect compared to curcumin. Further
research should be conducted to examine the role of curcumin oxidative degradation
products in other biological models.
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APPENDIX A
EFFECT OF TRICLOCARBAN ON ANIMAL BODY WEIGHT
The consumption of polyunsaturated omega-6 fatty acid is high in the Western world
due to the use of vegetable oil, which contains linoleic acid. On the other hand, omega-3
fatty acid intake is low in the Western world, and some studies have shown a correlation
between high omega-6 to omega-3 ratio and obesity. In obese mothers, the ratio of
omega-6 to omega-3 fatty acid in breast milk was greater than in normal-weight mothers
80

. Omega-6 fatty acids can be metabolized through the cytochrome P450 epoxygenase

pathway. First, the omega-6 arachidonic acid is metabolized by epxoygenase to form
epoxyeicosatrienoic acids (EET), which are quickly metabolized by soluble epoxide
hydrolase (sEH) 81. Blocking this enzyme increases tissue levels of EET, which may have
pro-obesity effects (unpublished results).
Triclocarban is an antibacterial agent used in personal care products such as hand
soaps. It has been found in human urine, raising concerns about the potential hazards of
continuous exposure to this bacteriocide 82. Schebb et al found that after a regular shower
using triclocarban-containing soaps, micromolar amounts of the compound could be
detected in the urine; furthermore, topical application of triclocarban was sufficient to
block sEH activity in mice 83. In other words, triclocarban may promote obesity by
increasing the concentration of EET, which is derived from omega-6 fatty acids. Based
on the available results, it is hypothesized that triclocarban promotes obesity by
increasing concentration of EET.

27

The first objective was to compare the weights of mice fed with 0.08% triclocarban
together with 10% corn oil compared to mice fed with 10% corn oil alone. Mice weight
was recorded twice a week for 6 weeks. Food intake was monitored and food was
changed twice per week. Student t-test was utilized to determine significant difference
between the two groups for each day the weights of the mice were recorded. However,
mice that were fed 0.08% triclocarban together with 10% corn oil gained weight more
slowly than mice fed with corn oil alone, thus contradicting our hypothesis (Figure 8). It
is likely that the dose of triclocarban used in this experiment induced toxicity effects in
the mice, leading to the loss in weight.
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Figure 8: Weights of mice fed with 10% corn oil alone (Control) or with 10% corn oil supplemented
with 0.08% triclocarban (TCC). Student t-test was performed between the groups for each pair of data
point (p<0.05).
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APPENDIX B
COMPARATIVE STABILITY OF CURCUMIN, DIDEMETHYLCURCUMIN,
AND DIMETHOXYCURCUMIN, AND THEIR EFFECTS ON NITRIC OXIDE
PRODUCTION
Although curcumin has been reported for its numerous health benefits, it is also
metabolically unstable. Furthermore, in buffers at physiological pH, curcumin degrades
rapidly 29. Due to its instability, there is a need for a stable curcumin analogue that is as
effective as curcumin. Recent data have suggested that methoxylating or hydroxylating
the functional groups on curcumin’s phenolic rings may affect curcumin activity. For
example, didemethylcurcumin (a curcumin analogue where all methoxy groups were
replaced with hydroxyl groups) showed higher antioxidant activity than curcumin,
whereas whereas dimethoxycurcumin (an analogue where all hydroxyl groups were
replaced with hydroxyl groups) showed no antioxidant effect 84. The result suggests a
possible structure relationship between the functional groups found on the curcumin’s
benzene rings and the activity of the curcumin or its analogue. While the effects of
curcumin have been compared with either didemethylcurcumin or dimethoxycurcumin in
several biological studies 67-69,85-88, no systematic biological study has been done on the
structural relationship activity of both analogues compared to curcumin. Here, the
comparative effects of curcumin and the two analogues on nitric oxide production were
examined. Additionally, HPLC analysis of intracellular curcumin and its analogues was
also conducted to examine the stability of each compound within the cells after treatment.
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RAW 264.7 cells were seeded in complete media and were treated with varying doses
of curcumin, didemethylcurcumin, or dimethoxycurcumin, with or without 0.5 μg/mL
LPS. Nitric oxide measurement was performed as described in Materials and Methods in
Chapter 2. For HPLC analysis, cells were treated with 20 μM of each treatment
compound without LPS stimulation; after 24 or 48 hours of incubation, the medium was
removed. Plates were rinsed with ice-cold PBS, and cells were lysed with RIPA buffer to
release intracellular treatment compounds.
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Ethyl acetate was used to extract the treatments from the buffer and was evaporated in a
vacuum centrifuge. Before HPLC analysis, samples were dissolved in methanol, and
reverse phase chromatography with a C-18 column was used. Prior to ethyl acetate
extraction, RIPA buffer was aliquoted to perform the BCA assay (see Materials and
Methods, Chapter 2). HPLC results were expressed as the weight of each treatment
compound remaining intracellularly over the total protein weight. Statistical calculations
were performed using ANOVA followed by the Tukey test with the assistance of the R
statistical software.
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The difference in nitric oxide inhibition between each compound was more apparent
after 48 hours; no significant differences among the compounds were found at each dose
in the 24 hour treatment (Figure 9). At 6.25 μM, dimethoxycurcumin was more effective
at inhibiting nitric oxide production than either curcumin or didemethylcurcumin,
suggesting the critical role of the methoxy functional groups in stabilizing the curcumin
analogue. Indeed, dimethoxycurcumin was found to be significantly more stable than
either curcumin or didemethylcurcumin after 24 and 48 hour treatments (Figure 10). On
the other hand, didemethylcurcumin was below the detection range was at both time
points, and curcumin's small peak at 24 hours decreased even further after 48 hours.
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APPENDIX C
CURCUMIN STABILIZED BY ANTIOXIDANTS CAN ATTENUATE LPSINDUCED NITRIC OXIDE PRODUCTION AND iNOS EXPRESSION
Curcumin is unstable in serum-free media at physiological pH 29; under these
conditions, curcumin can undergo oxidative degradation 30. Recently, Nimiya et al
discovered that curcumin can be stabilized by the addition of antioxidants 33. Details on
curcumin oxidative degradation can be found in Chapter 1. The objective of this study
was to compare the anti-inflammatory effects of curcumin dissolved in free media versus
curcumin co-dissolved with antioxidants in the same media.
RAW 264.7 cells were seeded in complete media and were treated with 6.25 μM
curcumin and/or 2.9 μM of a given antioxidant in serum-free basal medium.
Inflammation was stimulated with 0.5 μg/mL LPS. Nitric oxide measurement, cell
viability, and Western blotting were performed as described in the Materials and Methods
section of chapter 2. For statistical analysis, one-way ANOVA was performed for all
groups followed by Dunnett’s test.
Treatment with curcumin alone or antioxidant alone did not significantly decrease
LPS-induced nitric oxide production. However, their combination significantly induced
LPS-induced nitric oxide production (Figure 11). Furthermore, curcumin combined with
antioxidant significantly decreased LPS-induced iNOS expression (Figure 12). These
results suggest that the antioxidants increase curcumin’s efficacy by stabilizing curcumin,
which would otherwise undergo oxidative degradation.
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Figure 11: Nitric oxide production of LPS-induced RAW 264.7 cells treated with curcumin and/or
Trolox, sodium ascorbate (SA), caffeic acid (CA), or gallic acid (GA).
Neither curcumin nor antioxidant alone inhibited nitric oxide production, but both compounds
synergistically decreased nitric oxide production. Nitrite concentration was calculated as the fraction
of the absorbance of the LPS only control. Results are expressed as meanS.D.
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